Therapy for portal hypertension: What is our pipeline?

Hepatology

Volumn 49, Issue 1, 2009, Pages 4-5

  Shah, Vijay ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; NITRIC OXIDE; NITRIC OXIDE DONOR; PLATELET DERIVED GROWTH FACTOR; PROTEIN TYROSINE KINASE INHIBITOR; VASCULOTROPIN; VASCULOTROPIN A;

ANTIHYPERTENSIVE THERAPY; DRUG INDUSTRY; DRUG RESEARCH; DRUG TARGETING; NOTE; PATHOPHYSIOLOGY; PORTAL HYPERTENSION; PORTAL VEIN BLOOD PRESSURE; PRIORITY JOURNAL; CARDIOVASCULAR SYSTEM; DRUG DESIGN; EDITORIAL; HUMAN; LIVER; NEOVASCULARIZATION (PATHOLOGY); PHYSIOLOGY;

CARDIOVASCULAR SYSTEM; DRUG DESIGN; HUMANS; HYPERTENSION, PORTAL; LIVER; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58949092178     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.22687     Document Type: Note

References (12)

1. Reuben A, Groszmann R. Portal hypertension: A history. In: Sanyal A, Shah V, eds. Portal Hypertension. Totowa, NJ: Humana Press. In press.
2. Dunn W, Shah V. Hepatic macrocirculation: Portal hypertension as a disease paradigm of endothelial cell significance and heterogeneity In: Aird W, ed. Endothelial Biomedicine. Cambridge, UK: Cambridge University Press; 2007:1239-1247.
3. Iwakiri Y, Groszmann RJ. The hyperdynamic circulation of chronic liver diseases: From the patient to the molecule. HEPATOLOGY 2006;43(Suppl): S121-S131.
4. Semela D, Das A, Langer DA, Kang N, Leof E, Shah VH. PDGF signaling through ephrin-B2 regulates hepatic vascular structure and function. Gastroenterology 2008;135:671-679.
5. Liu S, Premont RT, Kontos CD, Zhu S, Rockey DC. A crucial role for GRK2 in regulation of endothelial cell nitric oxide synthase function in portal hypertension. Nat Med 2005;11:952-958.
6. Fernandez M, Vizzutti F, Garcia-Pagan J, Rodes J, Bosch J. Anti-VEGF receptor-2 monoclonal antibody prevents portal-systemic collateral vessel formation in portal hypertensive mice. Gastroenterology 2004;126:886-894.
7. Poynard T, Cales P, Pasta L, Ideo G, Pascal JP, Pagliaro L, et al. Betaadrenergic-antagonist drugs in the prevention of gastrointestinal bleeding in patients with cirrhosis and esophageal varices. An analysis of data and prognostic factors in 589 patients from four randomized clinical trials. Franco-Italian Multicenter Study Group. N Engl J Med 1991;324:1532-1538.
8. Zafra C, Abraldes J, Turnes J, Berzigotti A, Fernandez Zapico M, Garcia-Pagan J, et al. Simvastatin enhances hepatic nitric oxide production and decreases the hepatic vascular tone in patients with cirrhosis. Gastroenterology 2004;126:749-755.
9. Trebicka J, Hennenberg M, Laleman W, Shelest N, Biecker E, Schepke M, et al. Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho-kinase and activation of endothelial nitric oxide synthase. HEPATOLOGY 2007;46:242-253.
10. Tugues S, Fernandez-Varo G, Munoz-Luque J, Ros J, Arroyo V, Rodes J, et al. Antiangiogenic treatment with sunitinib ameliorates inflammatory infiltrate, fibrosis, and portal pressure in cirrhotic rats. HEPATOLOGY 2007; 46:1919-1926.
11. Lee JS, Semela D, Iredale J, Shah VH. Sinusoidal remodeling and angiogenesis: A new function for the liver-specific pericyte? HEPATOLOGY 2007; 45:817-825.
12. Laleman W, Van Landeghem L, Van der Elst I, Zeegers M, Fevery J, Nevens F. Nitroflurbiprofen, a nitric oxide-releasing cyclooxygenase inhibitor, improves cirrhotic portal hypertension in rats. Gastroenterology 2007;132:709-719.